Fate Therapeutics Croissance future

Future contrôle des critères 0/6

Les bénéfices de Fate Therapeutics devraient diminuer de 9.2% par an tandis que son chiffre d'affaires annuel devrait croître de 8.8% par an. Le BPA devrait croître de de 2.1% par an. Le rendement des capitaux propres devrait être -57.7% dans 3 ans.

Informations clés

-9.2%

Taux de croissance des bénéfices

2.1%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.4%
Taux de croissance des recettes	8.8%
Rendement futur des capitaux propres	-57.7%
Couverture par les analystes	Good
Dernière mise à jour	18 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Nov 20

Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Aug 21

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Aug 11

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Apr 29

Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Apr 23

Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Feb 16

Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks

Jan 26

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

Dec 19

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

Sep 08

Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

Jun 07

Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

May 08

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Apr 17

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Jan 10

Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Sep 22

Fate Therapeutics: Yes For Speculators, No For Defensive Investors

Aug 30

Needham initiates Fate coverage Therapeutics on potential of stem cell therapies

Jul 28

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:FATE - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	4	-229	-163	-119	6
12/31/2025	4	-221	-167	-170	15
12/31/2024	14	-186	-128	-129	13
9/30/2024	13	-178	-133	-132	N/A
6/30/2024	12	-176	-141	-141	N/A
3/31/2024	6	-190	-140	-137	N/A
12/31/2023	64	-161	-138	-132	N/A
9/30/2023	106	-173	-184	-171	N/A
6/30/2023	119	-212	-209	-188	N/A
3/31/2023	137	-235	-241	-212	N/A
12/31/2022	96	-282	-284	-248	N/A
9/30/2022	69	-294	-290	-243	N/A
6/30/2022	68	-254	-275	-221	N/A
3/31/2022	63	-233	-257	-200	N/A
12/31/2021	56	-212	-214	-163	N/A
9/30/2021	55	-197	-148	-113	N/A
6/30/2021	48	-212	-131	-111	N/A
3/31/2021	40	-185	-47	-40	N/A
12/31/2020	31	-173	-44	-39	N/A
9/30/2020	18	-149	-49	-44	N/A
6/30/2020	13	-117	-39	-33	N/A
3/31/2020	11	-112	-99	-92	N/A
12/31/2019	11	-98	-91	-83	N/A
9/30/2019	10	-86	-75	-69	N/A
6/30/2019	8	-76	-58	-52	N/A
3/31/2019	6	-72	-47	-44	N/A
12/31/2018	5	-67	-41	-39	N/A
9/30/2018	4	-63	-40	-38	N/A
6/30/2018	4	-57	N/A	-45	N/A
3/31/2018	4	-47	N/A	-42	N/A
12/31/2017	4	-43	N/A	-37	N/A
9/30/2017	4	-38	N/A	-34	N/A
6/30/2017	4	-36	N/A	-31	N/A
3/31/2017	4	-35	N/A	-30	N/A
12/31/2016	4	-33	N/A	-30	N/A
9/30/2016	4	-33	N/A	-29	N/A
6/30/2016	4	-31	N/A	-29	N/A
3/31/2016	4	-30	N/A	-19	N/A
12/31/2015	2	-30	N/A	-18	N/A
9/30/2015	1	-29	N/A	-18	N/A
6/30/2015	0	-28	N/A	-16	N/A
3/31/2015	N/A	-27	N/A	-24	N/A
12/31/2014	N/A	-26	N/A	-22	N/A
9/30/2014	N/A	-25	N/A	-21	N/A
6/30/2014	0	-25	N/A	-19	N/A
3/31/2014	0	-24	N/A	-17	N/A
12/31/2013	1	-21	N/A	-15	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: FATE devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: FATE devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: FATE devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de FATE ( 8.8% par an) devrait croître plus lentement que le marché de US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de FATE ( 8.8% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: FATE devrait être non rentable dans 3 ans.

Fate Therapeutics Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates increase by 32%

Price target decreased by 7.7% to US$7.20

Consensus revenue estimates decrease by 21%, EPS upgraded

Price target increased by 19% to US$7.53

Price target decreased by 11% to US$6.50

Price target decreased by 8.8% to US$6.63

Recent updates

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Fate Therapeutics, Inc. Presents Initial Clinical and Translational Data from its Phase 1 Study of FT522 in Relapsed / Refractory B-Cell Lymphoma at American College of Rheumatology Convergence

Fate Therapeutics, Inc. Highlights Cancer-Selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-Cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Fate Therapeutics, Inc. Appoints Neely Mozaffarian to its Board of Directors

Fate Therapeutics, Inc. Appoints J. Scott Wolchko as Principal Financial and Accounting Officer

Consensus revenue estimates increase by 32%

Price target decreased by 7.7% to US$7.20

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Fate Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Fate Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.999997 million.

Fate Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $79.999997 million.

New minor risk - Shareholder dilution

Fate Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.999997 million.

Consensus revenue estimates decrease by 21%, EPS upgraded

Price target increased by 19% to US$7.53

Full year 2023 earnings: EPS exceeds analyst expectations

Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Fate Therapeutics, Inc. to Report Q4, 2023 Results on Feb 26, 2024

Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks

Founder recently sold US$63k worth of stock

Founder notifies of intention to sell stock

Fate Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

Price target decreased by 11% to US$6.50

General Counsel & Corporate Secretary notifies of intention to sell stock

Price target decreased by 8.8% to US$6.63

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fate Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Share price stability

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fate Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Yu-Waye (Wayne) Chu Intends to Resign as Chief Medical Officer of Fate Therapeutics, Inc. Effective as of July 14, 2023

Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

Consensus revenue estimates increase by 36%

Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

Fate Therapeutics, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 54%, EPS downgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Fate Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc

Founder recently sold US$241k worth of stock

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Now 40% undervalued after recent price drop

Fate Therapeutics, Inc. Expects to Terminate Mark Plavsic as Chief Technical Officer, Effective as of March 6, 2023

Price target decreased to US$59.15

Price target decreased to US$61.10

Fate Therapeutics Announces Clinical Safety and Activity Data of First-Ever iPSC-Derived Car T-Cell Therapy

Insufficient new directors

Price target decreased to US$66.29

Third quarter 2022 earnings released: US$0.86 loss per share (vs US$0.45 loss in 3Q 2021)

Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Fate Therapeutics: Yes For Speculators, No For Defensive Investors

Chief Financial Officer recently sold US$153k worth of stock

Price target decreased to US$74.05

Consensus forecasts updated

Fate Therapeutics Announces Preclinical Publication Highlighting Derivation of CD8aß T Cells from TCR-CAR+ Induced Pluripotent Stem Cells

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Needham initiates Fate coverage Therapeutics on potential of stem cell therapies

Founder notifies of intention to sell stock

Chief Research & Development Officer exercised options and sold US$472k worth of stock

Chief Technical Officer recently sold US$92k worth of stock